![Joseph Kekst](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph Kekst
Fondateur chez BoxCar Partners LLC
Postes actifs de Joseph Kekst
Sociétés | Poste | Début | Fin |
---|---|---|---|
Nirogy Therapeutics, Inc.
![]() Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | Directeur/Membre du Conseil | 01/12/2020 | - |
Asylia Therapeutics, Inc.
![]() Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Directeur/Membre du Conseil | - | - |
BoxCar Partners LLC | Fondateur | - | - |
Weizmann Institute of Science | Directeur/Membre du Conseil | - | - |
Historique de carrière de Joseph Kekst
Anciens postes connus de Joseph Kekst
Sociétés | Poste | Début | Fin |
---|---|---|---|
IMMUNEERING CORPORATION | Directeur/Membre du Conseil | 16/12/2019 | 01/01/2021 |
Corporate Officer/Principal | 01/01/2021 | 01/08/2021 | |
Sporos Bioventures, Inc.
![]() Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Fondateur | - | - |
Formation de Joseph Kekst
Brandeis University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Israël | 2 |
Opérationnelle
Director/Board Member | 4 |
Founder | 2 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
IMMUNEERING CORPORATION | Health Technology |
Entreprise privées | 4 |
---|---|
Nirogy Therapeutics, Inc.
![]() Nirogy Therapeutics, Inc. BiotechnologyHealth Technology Nirogy Therapeutics, Inc. is an American biotechnology company that operates in the healthcare industry. The company is based in N/A. The company was founded in 2014 by Vincent Sandanayaka, Jaime Escobedo. Simon C. Pedder has been the CEO of the company since 2022. | Health Technology |
Asylia Therapeutics, Inc.
![]() Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | Health Technology |
BoxCar Partners LLC | |
Sporos Bioventures, Inc.
![]() Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
- Bourse
- Insiders
- Joseph Kekst
- Expérience